Literature DB >> 15955381

Possible novel index determined by the glucose clamp test for selection of a suitable therapy for each type 2 diabetic patient.

Shin-Ichi Gorogawa1, Hideaki Kaneto, Munehide Matsuhisa, Kentaro Ohtoshi, Dan Kawamori, Yoji Hazama, Kazutomi Yoshiuchi, Yoshimitsu Yamasaki.   

Abstract

The hallmark of type 2 diabetes is insulin resistance and insufficient insulin secretion, and appropriate therapy should be selected for each patient. In this study, to establish some index to select suitable therapy for each patient, we evaluated insulin sensitivity and insulin secretion with euglycemic hyperinsulinemic clamp and hyperglycemic clamp tests, respectively, and found that specific GIR index (GIRxIRI (90)) could be a useful marker to select suitable therapy for each type 2 diabetic patient (GIR: glucose infusion rate in euglycemic hyperinsulinemic clamp test; IRI (90): plasma insulin level 90 min after starting the hyperglycemic clamp test).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15955381     DOI: 10.1016/j.diabres.2004.10.006

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Computational assessment of insulin secretion and insulin sensitivity from 2-h oral glucose tolerance tests for clinical use for type 2 diabetes.

Authors:  Masayoshi Seike; Takeo Saitou; Yasuhiro Kouchi; Takeshi Ohara; Munehide Matsuhisa; Kazuhiko Sakaguchi; Koji Tomita; Keisuke Kosugi; Atsunori Kashiwagi; Masato Kasuga; Masaru Tomita; Yasuhiro Naito; Hiromu Nakajima
Journal:  J Physiol Sci       Date:  2011-05-19       Impact factor: 2.781

2.  Accuracy and Time Delay of Glucose Measurements of Continuous Glucose Monitoring and Bedside Artificial Pancreas During Hyperglycemic and Euglycemic Hyperinsulinemic Glucose Clamp Study.

Authors:  Akio Kuroda; Satoshi Taniguchi; Yuko Akehi; Hiroyasu Mori; Motoyuki Tamaki; Reiko Suzuki; Yinhua Otsuka; Munehide Matsuhisa
Journal:  J Diabetes Sci Technol       Date:  2017-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.